Two reports suggested an increase of mature CD56+CD57+CD62L− NK cell numbers in CML patients PB, that was associated with successful Imatinib discontinuation and deep molecular response in dasatinib treated patients [159,160]. This evidence concerns the gene NCAM1 and chronic myelogenous leukemia, BCR-ABL1 positive.